Control of drug-resistant tuberculosis
References (17)
- et al.
Multidrug-resistant tuberculosis and its control
Res Microbiol
(1993) - et al.
Surveillance of resistance to antituberculosis drugs in developing countries
Tubercle Lung Dis
(1994) - et al.
Drug-resistant tuberculosis
Clin Chest Med
(1989) - et al.
The impact of human immunodeficiency virus infection on tuberculosis and its control
Chest
(1991) - et al.
Nationwide Survey of Drug-Resistant Tuberculosis in the United States
JAMA
(1994) Drug resistance and tuberculosis elimination
Bull Int Union Tuberc Lung Dis
(1990)Drug Resistance in Tuberculosis
- et al.
Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection
N Engl J Med
(1993)
Cited by (40)
Role of acceptability barriers in delayed diagnosis of Tuberculosis: Literature review from high burden countries
2016, Acta TropicaCitation Excerpt :Multidrug-/extensively drug-resistant (MDR/XDR) TB cases, have significantly lower cure rates (40%) compared to drug susceptible cases (95%) (World Health Organization, 2013a). Available evidence indicates that M/XDR-TB has to be considered a predominantly man-made phenomenon, since human activities (e.g. improper treatment) are the main contributors to the development of the TB-bacteria resistance and the poor administration of M/XDR-TB problem promotes direct transmissions of resistant strains (Lambregts-van Weezenbeek and Veen, 1995; World Health Organization, 2008; Ye et al., 1997). Concentration of over 95% of TB-cases/deaths in low and middle-income countries (World Health Organization, 2013b), where suboptimal socioeconomic and demographic environment, coupled with the lack of preventing, diagnostic and treating facilities, create favorable conditions for the spread of disease (World Health Organization, 2013a), demonstrates transition from “treatment-generated to transmission-generated MDR-TB” (Andrews et al., 2008; Suen et al., 2014).
Anti-TB drug resistance in Tanga, Tanzania: A cross sectional facility-base prevalence among pulmonary TB patients
2015, Asian Pacific Journal of Tropical MedicineCitation Excerpt :Treatment of multi-drug resistant-TB (MDR-TB) is undoubtedly costly and requires longer treatment with more toxic drugs compared to drug susceptible TB [5,6]. Incorrect drug regimes, non-adherence to treatment, transmission in congregate settings, substandard drug quality, as well as erratic drug supply are key risk factors for drug resistance development [7,8]. Several studies have reported unacceptably high mortality rates among HIV-infected patients with MDR-TB [9,10].
Prevalence of multi-drug resistant tuberculosis in Karachi, Pakistan: identification of at risk groups
2010, Transactions of the Royal Society of Tropical Medicine and HygieneTreatment outcomes and relapses of pulmonary tuberculosis in Lazio, Italy, 1999-2001: a six-year follow-up study
2008, International Journal of Infectious DiseasesCitation Excerpt :The highest risk of failure was observed in patients from Eastern Europe and Southeast Asia, which is consistent with this hypothesis. Although no differences were found between drugs prescribed to non-Italians and Italians, other aspects of treatment that were not analyzed here3,12,16,25,26 could have made treatment inadequate in foreign-born patients. A misclassification of previous treatment could also have contributed to these results.
An evaluation of the actual incidence of tuberculosis in French Guiana using a capture-recapture model
2006, Microbes and InfectionCitation Excerpt :Active TB infection requires treatment with a combination of three or four antibiotics for at least six months. Failure to complete the full course of drug therapy can lead to the emergence of drug-resistant strains of mycobacteria [2,3]. This so-called acquired resistance, as opposed to primary resistance [4], severely limits effective treatment options.
Trends and Progress on Antibiotic-Resistant Mycobacterium tuberculosis and Genes in relation to Human Immunodeficiency Virus
2023, Canadian Journal of Infectious Diseases and Medical Microbiology